Document is current
Any future updates will be listed below
-
Authors
Calabrò, Luana
Caruso, Francesca P.
Covre, Alessia
Noviello, Teresa M. R. https://orcid.org/0000-0002-3411-6752
Lofiego, Maria F.
Tufano, Rossella https://orcid.org/0000-0002-9158-3533
Ferraro, Luigi
Grisolia, Piera
De Falco, Antonio https://orcid.org/0000-0003-2396-3101
Lagano, Vincenzo https://orcid.org/0000-0002-5965-0361
Sgambelluri, Francesco
Sabella, Giovanna
Rossi, Giulia
Gibilisco, Giulia
Marzani, Francesco https://orcid.org/0009-0005-9399-4511
Bello, Emma
Simonetti, Elena
D’Alonzo, Vincenzo https://orcid.org/0000-0002-9264-377X
Caraglia, Michele
Coral, Sandra
De Angelis, Antonina
Cerbone, Luigi
Delfanti, Sara https://orcid.org/0000-0002-9862-7340
Giannarelli, Diana
Grosso, Federica
Di Giacomo, Anna Maria
Milione, Massimo
Mortarini, Roberta
Anichini, Andrea
Ceccarelli, Michele https://orcid.org/0000-0002-4702-6617
Maio, Michele
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 25 March 2026
First Online: 27 April 2026
Competing interests
: L. Calabrò has received compensation for educational activities from Bristol Myers Squibb, AstraZeneca, Regeneron, Merck Sharp & Dohme, Roche and Viatris. A.C. and S.C. own shares in Epigen Therapeutics. L. Cerbone reports support for attending meetings or travel from Pierre Fabre. F.G. reports consulting fees and support for attending meetings or travel from Merck Sharp & Dohme, Novocure, Bristol Myers Squibb, Boehringer Ingelheim, PharmaMar, Novartis and Pierre Fabre; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Novocure; and participation on a data safety monitoring board or advisory board for Merck Sharp & Dohme, Novocure, Bristol Myers Squibb, PharmaMar, Novartis and Pierre Fabre. A.M.D.G. has served as consultant and/or advisor to Incyte, Pierre Fabre, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme and Sanofi, and has received compensation for educational activities from Bristol Myers Squibb, Merck Sharp & Dohme, Pierre Fabre and Sanofi. M. Milione has served as consultant and/or advisor to Novartis, Ipsen, Roche, Sakura Finetek, Leica, Diapath, Bioptica and Merck Sharp & Dohme, and has received financial support for clinical trials from Ignyta, Roche, ADOPT BBMRI-ERIC, TRANSCAN2 and Fondazione IRCCS Istituto Nazionale Tumori Milano. M. Ceccarelli received funding from Moderna Therapeutics and is the founder and shareholder of Immunomica. M. Maio has served as consultant and/or advisor to Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, GlaxoSmithKline, Sciclone, Sanofi, Alfasigma and Merck Serono, and shareholder in Epigen Therapeutics. The remaining authors declare no competing interests.
